Capricor Therapeutics(CAPR)
$11.22+2.35 (+26.49%)
CAPR
Capricor Therapeutics financials statements
$11.22
At close:+2.35 (+26.49%)
Want to see CAPR full AI Analyst Report?
Capricor Therapeutics (CAPR) Ratios
1,408 Followers
Capricor Therapeutics Ratios
CAPR's free cash flow for Q2 2026 was $-37.39M. For the 2026 fiscal year, CAPR's free cash flow was decreased by $-5.90M and operating cash flow was $-31.49M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.01 | 7.77 | 1.63 | 1.82 | 8.82 |
| Quick Ratio | 9.01 | 7.77 | 1.63 | 1.82 | 8.82 |
| Cash Ratio | 8.03 | 0.54 | 0.47 | 0.41 | 8.44 |
| Solvency Ratio | -2.06 | -1.56 | -0.59 | -0.74 | -1.99 |
| Operating Cash Flow Ratio | -1.95 | -1.90 | -0.82 | 0.21 | -4.07 |
| Short-Term Operating Cash Flow Coverage | -19.26 | -47.91 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 272.78M | $ 138.37M | $ 14.72M | $ 4.58M | $ 26.47M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.03 | 0.04 | 0.05 | 0.07 |
| Debt-to-Equity Ratio | 0.06 | 0.03 | 0.10 | 0.22 | 0.09 |
| Debt-to-Capital Ratio | 0.06 | 0.03 | 0.09 | 0.18 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.16 | 1.17 | 2.60 | 4.25 | 1.32 |
| Debt Service Coverage Ratio | -15.01 | -46.77 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -35.51 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.45 | 0.14 | 0.08 | 0.10 | 0.12 |
| Net Debt to EBITDA | 2.70 | 0.17 | 0.54 | 0.24 | 1.55 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -124.37% | -44.76% | -755.07% | 100.00% |
| EBIT Margin | 0.00% | -181.71% | -95.63% | -1163.93% | -8549.86% |
| EBITDA Margin | 0.00% | -175.31% | -91.39% | -1143.04% | -8449.54% |
| Operating Profit Margin | 0.00% | -191.13% | -95.63% | -1163.93% | -8549.86% |
| Pretax Profit Margin | 0.00% | -181.71% | -88.52% | -1137.37% | -8175.86% |
| Net Profit Margin | 0.00% | -181.71% | -88.52% | -1137.37% | -8175.86% |
| Continuous Operations Profit Margin | 0.00% | -181.71% | -88.52% | -1137.37% | -8175.86% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.14% | 95.07% | 92.56% | 97.72% | 95.63% |
| Return on Assets (ROA) | -29.51% | -23.74% | -37.95% | -57.93% | -48.45% |
| Return on Equity (ROE) | -34.35% | -27.82% | -98.61% | -246.22% | -63.83% |
| Return on Capital Employed (ROCE) | -33.78% | -28.48% | -87.67% | -112.03% | -56.29% |
| Return on Invested Capital (ROIC) | -33.40% | -28.32% | -85.34% | -109.22% | -55.67% |
| Return on Tangible Assets | -29.51% | -23.74% | -37.95% | -57.93% | -48.45% |
| Earnings Yield | -7.83% | -8.33% | -17.02% | -30.62% | -29.60% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 2.15 | 2.43 | 4.66 | 0.63 |
| Payables Turnover | 0.00 | 15.22 | 5.84 | 4.51 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 3.24 | 3.31 | 0.37 | 0.05 |
| Asset Turnover | 0.00 | 0.13 | 0.43 | 0.05 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.28 | 1.29 | 0.10 | 0.01 |
| Cash Conversion Cycle | 0.00 | 145.95 | 87.87 | -2.55 | 583.87 |
| Days of Sales Outstanding | 0.00 | 169.93 | 150.36 | 78.33 | 583.87 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 23.99 | 62.49 | 80.88 | 0.00 |
| Operating Cycle | 0.00 | 169.93 | 150.36 | 78.33 | 583.87 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.50 | -1.14 | -0.96 | 0.20 | -0.73 |
| Free Cash Flow Per Share | -1.56 | -1.18 | -1.03 | 0.06 | -0.78 |
| Dividend Paid and CapEx Coverage Ratio | -24.04 | -25.99 | -12.50 | 1.46 | -14.05 |
| Capital Expenditure Coverage Ratio | -24.04 | -25.99 | -12.50 | 1.46 | -14.05 |
| Operating Cash Flow Coverage Ratio | -3.89 | -8.29 | -11.45 | 1.92 | -5.86 |
| Operating Cash Flow to Sales Ratio | 0.00 | -1.80 | -1.02 | 1.93 | -68.64 |
| Free Cash Flow Yield | -5.42% | -8.55% | -21.11% | 1.64% | -26.62% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.77 | -12.00 | -5.88 | -3.27 | -3.38 |
| Price-to-Sales (P/S) Ratio | 0.00 | 21.82 | 5.20 | 37.15 | 276.24 |
| Price-to-Book (P/B) Ratio | 4.39 | 3.34 | 5.79 | 8.04 | 2.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -18.45 | -11.70 | -4.74 | 60.87 | -3.76 |
| Price-to-Operating Cash Flow Ratio | -19.21 | -12.15 | -5.12 | 19.28 | -4.02 |
| Price-to-Earnings Growth (PEG) Ratio | -0.13 | -0.31 | 0.20 | -0.09 | 2.97 |
| Enterprise Value Multiple | -10.70 | -12.28 | -5.15 | -3.01 | -1.72 |
| Enterprise Value | 1.07B | 479.56M | 118.49M | 87.73M | 35.64M |
| EV to EBITDA | -10.70 | -12.28 | -5.15 | -3.01 | -1.72 |
| EV to Sales | 0.00 | 21.53 | 4.71 | 34.38 | 145.52 |
| EV to Free Cash Flow | -14.73 | -11.55 | -4.29 | 56.35 | -1.98 |
| EV to Operating Cash Flow | -15.35 | -11.99 | -4.63 | 17.84 | -2.12 |
| Tangible Book Value Per Share | 6.58 | 4.13 | 0.84 | 0.48 | 1.36 |
| Shareholders’ Equity Per Share | 6.58 | 4.13 | 0.84 | 0.48 | 1.36 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.63 | 0.94 | 0.10 | 0.01 |
| Net Income Per Share | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.03 | 1.00 | 0.93 | 0.98 | 0.96 |
| Research & Development to Revenue | 0.00 | 2.24 | 1.45 | 8.55 | 55.42 |
| SG&A to Revenue | 0.00 | 0.67 | 0.51 | 4.09 | 31.08 |
| Stock-Based Compensation to Revenue | 0.00 | 0.44 | 0.29 | 1.75 | 12.11 |
| Income Quality | 0.66 | 0.99 | 1.15 | -0.17 | 0.84 |
Currency in USD
